Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH), the world's leading healthcare diagnostics company, is proud to announce that IDG's Computerworld recently recognized Dimitris Agrafiotis, Ph.D., chief data officer and head of technology products for Covance Drug Development, as a 2017 Premier 100 Technology Leaders honoree. This year's Premier 100 spotlights 100 leaders from both the technology and business sides of companies for their exceptional technology leadership and innovative approaches to business challenges. Covance is the drug development business of LabCorp. "The Premier 100 awards program highlights the exceptional work of an elite group of IT executives who are leading their organizations through times of unprecedented change. They are using technology to drive high-stakes business projects and create dynamic growth in their organizations," said Scot Finnie, editor in chief of Computerworld. "These 100 men and women are not only strategic business thinkers, but also team leaders who recognize the importance of recruiting and retaining the brightest talent to enable digital transformation and harness the opportunities of cloud, big data, mobile and social. We're pleased to recognize their leadership and honor their achievements." "We are proud to see Dimitris recognized as an innovative leader for the contributions by him and his informatics team in developing and bringing Xcellerate ® Informatics to market," said Lance Berberian, senior vice president and chief information officer of LabCorp. "Their work advances LabCorp's mission to improve health and improve lives by helping bring innovative medicines to patients faster." Xcellerate is a first-of-its-kind technology solution that integrates, analyzes and visualizes relevant clinical-trial data in near real time to mitigate risk, protect patient safety and drive better and faster clinical-trial results, for a single study or across an entire portfolio of trials. Berberian added, "The Covance Drug Development team is transforming the drug development process, and Dimitris and his colleagues are playing a critical role in the transformation by combining deep industry knowledge with extraordinary technical skills to create highly functional, sophisticated software that delivers actionable insights to trial sponsors."